Company intelligence / Profile preview

TransMedics

Andover, Massachusetts, United Statestransmedics.com ↗

Ownership: Public · TMDX
Development stage: Other

Overview

TransMedics’ Organ Care System (OCS™) platform has received FDA approval for use in heart, lung, and liver transplantation. Clinical trials have demonstrated that OCS yields superior outcomes compared to traditional static cold storage methods. The company completed approximately 2,300 OCS transplants in the U.S. in 2023—a significant increase from previous years—and aims to reach a cumulative total of over 10,000 OCS transplants by 2028[5]. The technology enables longer transport times and improved organ viability.

Therapeutic areas: GastroenterologyPulmonologyCardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Financials

Market cap: $2.4B
Total revenue: $605.5M
Enterprise value: $2.8B

Beyond the preview

Go deeper on TransMedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TransMedics.